Lobeglitazone
- Generic Name
- Lobeglitazone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H24N4O5S
- CAS Number
- 607723-33-1
- Unique Ingredient Identifier
- MY89F08K5D
- Background
Lobeglitazone is an antidiabetic medication from the thiazolidinedione class of drugs. It primarily functions as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells. By activating PPAR-gamma and promoting the binding of insulin at fat cells, lobeglitazone thereby has been shown to reduce b...
- Indication
Lobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019. Lobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes.
- Associated Conditions
- -
- Associated Therapies
- -
Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT02338921
- Locations
- 🇰🇷
Soo Lim, Seongnam, Gyeonggi, Korea, Republic of
Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 190
- Registration Number
- NCT02315287
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of
Drug-drug Interaction Study(Lobeglitazone, Warfarin)
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2014-07-03
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT02002611
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.